FLAME试验中前列腺癌外照射放疗后晚期泌尿生殖系统毒性的尿道与膀胱剂量效应关系
基于FLAME试验(NCT01168479)全部队列,评估局限性前列腺癌常规分割外照射放疗后膀胱和尿道剂量与≥2级泌尿生殖系统毒性(CTCAE 3.0)至5年的剂量效应关系。混合模型分析显示膀胱D2 cm³和尿道D0.1 cm³剂量与毒性独立相关,调整后OR分别为1.14(95%CI 1.12-1.16,p<0.0001)和1.12(95%CI 1.11-1.14,p<0.0001);尿道和膀胱剂量还与尿频、尿潴留和尿失禁相关。作者认为进一步增加膀胱和尿道剂量将显著增加泌尿生殖系统毒性,局灶加量治疗计划应纳入尿道剂量约束。
要点
- 膀胱D2 cm³剂量与≥2级泌尿生殖系统毒性相关,调整后OR为1.14(95%CI 1.12-1.16,p<0.0001)。
- 尿道D0.1 cm³剂量与≥2级泌尿生殖系统毒性相关,调整后OR为1.12(95%CI 1.11-1.14,p<0.0001)。
- 尿道和膀胱剂量与尿频、尿潴留和尿失禁子域相关。
核心结论
- 进一步增加膀胱和尿道剂量将导致外照射放疗后泌尿生殖系统毒性显著增加。
- 作者认为局灶加量治疗计划应纳入尿道剂量约束。
- 作者认为未来研究应聚焦于在不增加尿道和其他危及器官剂量的前提下优化治疗以提高局灶加量剂量。
研究设计与样本
- 本研究基于FLAME试验(NCT01168479)全部队列,分析局限性前列腺癌患者接受常规分割外照射放疗后尿道和膀胱剂量与≥2级泌尿生殖系统毒性(CTCAE 3.0)至5年的剂量效应关系。
- 采用重复测量混合模型分析,调整年龄、糖尿病、T分期、基线≥1级泌尿生殖系统毒性和机构。
主要发现
- 膀胱D2 cm³剂量与≥2级泌尿生殖系统毒性存在剂量效应关系,调整后OR为1.14(95%CI 1.12-1.16,p<0.0001)。
- 尿道D0.1 cm³剂量与≥2级泌尿生殖系统毒性存在剂量效应关系,调整后OR为1.12(95%CI 1.11-1.14,p<0.0001)。
- 尿道和膀胱剂量与尿频、尿潴留和尿失禁子域存在关联。
关键数值与推荐
- 膀胱D2 cm³剂量每增加1 Gy,≥2级泌尿生殖系统毒性调整后OR为1.14(95%CI 1.12-1.16,p<0.0001)。
- 尿道D0.1 cm³剂量每增加1 Gy,≥2级泌尿生殖系统毒性调整后OR为1.12(95%CI 1.11-1.14,p<0.0001)。
临床怎么用
- 作者认为局灶加量治疗计划应纳入尿道剂量约束。
- 作者认为未来研究应聚焦于在不增加尿道和其他危及器官剂量的前提下优化治疗以提高局灶加量剂量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE OR OBJECTIVES: The FLAME trial (NCT01168479) showed that by adding a focal boost to conventional fractionated EBRT in the treatment of localized prostate cancer, the five-year biochemical disease-free survival increased, without significantly increasing toxicity. The aim of the present study was to investigate the association between radiation dose to the bladder and urethra and genitourinary (GU) toxicity grade ≥2 in the entire cohort. MATERIAL AND METHODS: The dose-effect relations of the urethra and bladder dose, separately, and GU toxicity grade ≥2 (CTCAE 3.0) up to five years after treatment were assessed. A mixed model analysis for repeated measurements was used, adjusting for age, diabetes mellitus, T-stage, baseline GU toxicity grade ≥1 and institute. Additionally, the association between the dose and separate GU toxicity subdomains were investigated. RESULTS: Dose-effect relations were observed for the dose (Gy) to the bladder D2 cm3 and urethra D0.1 cm3, with adjusted odds ratios of 1.14 (95% CI 1.12-1.16, p < 0.0001) and 1.12 (95% CI 1.11-1.14, p < 0.0001), respectively. Additionally, associations between the dose to the urethra and bladder and the subdomains urinary frequency, urinary retention and urinary incontinence were observed. CONCLUSION: Further increasing the dose to the bladder and urethra will result in a significant increase in GU toxicity following EBRT. Focal boost treatment plans should incorporate a urethral dose-constraint. Further treatment optimization to increase the focal boost dose without increasing the dose to the urethra and other organs at risk should be a focus for future research, as we have shown that a focal boost is beneficial in the treatment of prostate cancer.
引用
- Groen VH, van Schie M, Zuithoff NPA, et al. Urethral and bladder dose-effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial. Radiother Oncol. 2021. PMID: 34968470. doi:10.1016/j.radonc.2021.12.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。